Clinical Trial Update: Expanded Access to Triheptanoin

View source ↗

Summary

Expanded access to triheptanoin is available for patients with long-chain fatty acid oxidation disorders, according to the clinical trials registry update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long-chain Fatty Acid Oxidation Disorders

Drugs mentioned

• Triheptanoin (triheptanoin)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Long Chain Fatty Acid Oxidation Disorders | Status: AVAILABLE